Ashley Ross, MD, PHD

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Lantheus
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Veracyte
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Astellas
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Myovant
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Bayer
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    TEMPUS
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Blue Earth
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Pfizer
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    Janssen
    Date added:
    Date updated:
    02/22/2023
  • Attribution:
    Self
    Type of financial relationship:
    Consultant or Advisor (Oncology)
    Ineligible company:
    GenomeDx Biosciences
    Date added:
    Date updated:
    02/22/2023
Return to PARPi: Precision Medicine in Advanced Prostate Cancer (2023)